Related Experiment Videos
Lipid-Lowering Efficacy and Safety of Obicetrapib Alone and as an Add on Therapy: A Meta-Analysis of Randomized
Mayank Jha1, Deep Chahodiya1, Kruti Matawala1
1From the Department of Internal Medicine, Government Medical College and New Civil Hospital, Surat, India.
Abstract:
Obicetrapib is a cholesteryl ester transfer protein inhibitor that demonstrated reductions in atherogenic lipoproteins. We systematically searched PubMed, Scopus, and Clinicaltrials.gov for relevant randomized controlled trials from inception until September 2, 2025 to evaluate the efficacy and safety outcomes of obicetrapib as a standalone and add-on therapy. The mean difference (MD) with 95% confidence intervals (CI) was pooled using a random effects model. A total of 3512 patients were included. Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001], non-high-density lipoprotein (HDL) cholesterol [MD, -32.04 (95% CI, -38.49 to -25.60), P < 0.001], apolipoprotein B [MD, -24.71 (95% CI, -30.79 to -18.63), P < 0.001] and apolipoprotein A [MD, -39.10 (95% CI, -45.35 to -32.85), P < 0.001]. It significantly increased total cholesterol [MD, +10.41 (95% CI, 3.68-17.15), P < 0.001], HDL cholesterol [MD, +147.98 (95% CI, 129.23-166.54), P < 0.001], apolipoprotein A1 [MD, 55.54 (95% CI, 43.37-67.71)], and apolipoprotein E [MD, 53.24 (95% CI, 39.04-67.44), P < 0.001]. As an add-on therapy to ezetimibe, obicetrapib yielded greater reduction in low-density lipoprotein [MD, -51.99 (95% CI, -61.61 to -42.37), P < 0.001] and non-HDL [MD, -50.32 (-55.42 to -45.21), P < 0.001]. No significant effects were observed when combined with statins.
Insights
Obicetrapib, a cholesteryl ester transfer protein inhibitor, significantly reduces atherogenic lipoproteins like LDL cholesterol and apolipoprotein B. It also increases HDL cholesterol, showing promise in lipid management.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Research
- Clinical Trial Analysis
Background:
- Atherogenic lipoproteins contribute significantly to cardiovascular disease risk.
- Cholesteryl ester transfer protein (CETP) inhibitors represent a therapeutic target for dyslipidemia.
- Obicetrapib has shown potential in reducing atherogenic lipoproteins.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of obicetrapib.
- To assess obicetrapib as both a standalone and add-on therapy.
- To analyze its effects on various lipid parameters and apolipoproteins.
Main Methods:
- Systematic literature search of PubMed, Scopus, and Clinicaltrials.gov.
- Inclusion of randomized controlled trials up to September 2, 2025.
- Meta-analysis using a random effects model to pool mean differences and 95% confidence intervals.
Main Results:
- Obicetrapib significantly reduced LDL cholesterol, non-HDL cholesterol, apolipoprotein B, and apolipoprotein A.
- Significant increases were observed in total cholesterol, HDL cholesterol, apolipoprotein A1, and apolipoprotein E.
- As add-on therapy to ezetimibe, obicetrapib showed greater reductions in LDL and non-HDL cholesterol.
Conclusions:
- Obicetrapib effectively reduces atherogenic lipoproteins and increases HDL cholesterol.
- It demonstrates significant efficacy as an add-on therapy, particularly with ezetimibe.
- Further research may explore its role in combination therapies, excluding statins based on current findings.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
01:21Drug Dosing: Obese Patients
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:26Atherosclerosis III: Management